Form 4 for PLRX PLIANT THERAPEUTICS, INC.
Accepted 2023-01-27 00:00:00 ET · period of report 2023-01-25 · accession 0001140361-23-003177 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-27 | 2023-01-26+ | PLRX | Coulie Bernard | Pres, CEO, Dir | M - OptEx | $2.08 | +30.0K | 255.1K | +13% | +$62.4K |
| DM | 2023-01-27 | 2023-01-26+ | PLRX | Coulie Bernard | Pres, CEO, Dir | S - Sale+OE | $35.49 | -30.0K | 240.1K | -11% | -$1.06M |
| DMI | 2023-01-27 | 2023-01-26+ | PLRX | Coulie Bernard | Pres, CEO, Dir | S - Sale+OE | $35.11 | -25.0K | 409.5K | -6% | -$877.7K |
| D | 2023-01-27 | 2023-01-25 | PLRX | Coulie Bernard | Pres, CEO, Dir | A - Grant | $0.00 | +146.3K | 240.1K | +156% | $0 |
| DM | 2023-01-27 | 2023-01-26 | PLRX | Coulie Bernard | Pres, CEO, Dir | M - OptEx | $0.00 | -30.0K | 187.4K | -14% | $0 |
| D | 2023-01-27 | 2023-01-25 | PLRX | Coulie Bernard | Pres, CEO, Dir | A - Grant | $0.00 | +206.3K | 206.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-27 | M | A | 15,000 | $2.08 | 255,112 | D | — | — | |
| 2 | Common | Common Stock | 2023-01-27 | S | D | 8,698 | $35.42 | 246,414 | D | — | — | (F6) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $35.85, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4. |
| 3 | Common | Common Stock | 2023-01-27 | S | D | 6,302 | $36.06 | 240,112 | D | — | — | (F7) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.87 to $36.45, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4. |
| 4 | Common | Common Stock | 2023-01-26 | S | D | 15,000 | $35.29 | 240,112 | D See footnote | — | — | (F5) Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| 5 | Common | Common Stock | 2023-01-27 | S | D | 221 | $36.64 | 409,317 | I | — | — | |
| 6 | Common | Common Stock | 2023-01-26 | M | A | 15,000 | $2.08 | 255,112 | D See footnote | — | — | (F5) Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| 7 | Common | Common Stock | 2023-01-25 | A | A | 146,300 | $0.00 | 240,112 | D See footnote | — | — | (F1) These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. (F5) Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| 8 | Common | Common Stock | 2023-01-26 | S | D | 15,000 | $35.10 | 419,317 | I | — | — | (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.43, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. |
| 9 | Common | Common Stock | 2023-01-27 | S | D | 9,779 | $35.09 | 409,538 | I | — | — | (F8) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.63 to $36.54, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) to this Form 4. |
| 10 | Derivative | Stock Option (right to buy) | 2023-01-26 | M | D | 15,000 | $0.00 | 172,380 | D | $2.08 · — to 2029-01-23 | 15,000 Common Stock | (F10) 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| 11 | Derivative | Stock Option (right to buy) | 2023-01-26 | M | D | 15,000 | $0.00 | 187,380 | D | $2.08 · — to 2029-01-23 | 15,000 Common Stock | (F10) 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| 12 | Derivative | Stock Option (right to buy) | 2023-01-25 | A | A | 206,300 | $0.00 | 206,300 | D | $34.65 · — to 2033-01-24 | 206,300 Common Stock | (F9) 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. |